Post by Dicot Pharma AB

We are pleased to participate in Aktiespararna’s investor event, Aktiedagarna, on June 9 in Stockholm. Our CEO, Elin Trampe, will present Dicot Pharma (in Swedish) and our drug candidate LIB-01, which is being developed as a novel, long-acting treatment for erectile dysfunction. We are currently preparing for a phase 2b clinical study of LIB-01 in Europe and the US - an important milestone in our continued clinical development. The presentation begins at 1:30 PM and can be followed live via the link. A recording will also be available after the event, including on our website. https://lnkd.in/dSrRd3Sc #LIB01 #erectiledysfunction #biotech #drugdevelopment